JP2018513135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513135A5 JP2018513135A5 JP2017549815A JP2017549815A JP2018513135A5 JP 2018513135 A5 JP2018513135 A5 JP 2018513135A5 JP 2017549815 A JP2017549815 A JP 2017549815A JP 2017549815 A JP2017549815 A JP 2017549815A JP 2018513135 A5 JP2018513135 A5 JP 2018513135A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- variable region
- scfv
- antibody variable
- fab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 39
- 108091008874 T cell receptors Proteins 0.000 claims description 34
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 34
- 102000027450 oncoproteins Human genes 0.000 claims description 30
- 108091008819 oncoproteins Proteins 0.000 claims description 30
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 230000035772 mutation Effects 0.000 claims description 20
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 10
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 210000000265 leukocyte Anatomy 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 102000001301 EGF receptor Human genes 0.000 claims description 4
- 108060006698 EGF receptor Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 102000015735 Beta-catenin Human genes 0.000 claims description 2
- 108060000903 Beta-catenin Proteins 0.000 claims description 2
- 102100030708 GTPase KRas Human genes 0.000 claims description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 2
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 238000002823 phage display Methods 0.000 claims description 2
- 238000002818 protein evolution Methods 0.000 claims description 2
- 102200044886 rs121913409 Human genes 0.000 claims description 2
- 102200006531 rs121913529 Human genes 0.000 claims description 2
- 102200006539 rs121913529 Human genes 0.000 claims description 2
- 102200006538 rs121913530 Human genes 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021072976A JP7304911B2 (ja) | 2015-03-23 | 2021-04-23 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
| JP2023063966A JP2023085528A (ja) | 2015-03-23 | 2023-04-11 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
| JP2026037548A JP2026090637A (ja) | 2015-03-23 | 2026-03-10 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136843P | 2015-03-23 | 2015-03-23 | |
| US62/136,843 | 2015-03-23 | ||
| US201562186455P | 2015-06-30 | 2015-06-30 | |
| US62/186,455 | 2015-06-30 | ||
| PCT/US2016/023673 WO2016154246A1 (en) | 2015-03-23 | 2016-03-23 | Hla-restricted epitopes encoded by somatically mutated genes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021072976A Division JP7304911B2 (ja) | 2015-03-23 | 2021-04-23 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513135A JP2018513135A (ja) | 2018-05-24 |
| JP2018513135A5 true JP2018513135A5 (cg-RX-API-DMAC10.html) | 2019-05-09 |
| JP6944877B2 JP6944877B2 (ja) | 2021-10-06 |
Family
ID=56977729
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549815A Active JP6944877B2 (ja) | 2015-03-23 | 2016-03-23 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
| JP2021072976A Active JP7304911B2 (ja) | 2015-03-23 | 2021-04-23 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
| JP2023063966A Pending JP2023085528A (ja) | 2015-03-23 | 2023-04-11 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
| JP2026037548A Pending JP2026090637A (ja) | 2015-03-23 | 2026-03-10 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021072976A Active JP7304911B2 (ja) | 2015-03-23 | 2021-04-23 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
| JP2023063966A Pending JP2023085528A (ja) | 2015-03-23 | 2023-04-11 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
| JP2026037548A Pending JP2026090637A (ja) | 2015-03-23 | 2026-03-10 | 体細胞変異遺伝子によりコードされるｈｌａ拘束性エピトープ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20180086832A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3286222A4 (cg-RX-API-DMAC10.html) |
| JP (4) | JP6944877B2 (cg-RX-API-DMAC10.html) |
| CN (2) | CN115873129A (cg-RX-API-DMAC10.html) |
| AU (3) | AU2016235251B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2980292A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016154246A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016154047A2 (en) * | 2015-03-20 | 2016-09-29 | Memorial Sloan-Kettering Cancer Center | Monoclonal antigen-binding proteins to intracellular oncogene products |
| CN110325205B (zh) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11851471B2 (en) | 2017-01-09 | 2023-12-26 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| EP3592776A4 (en) * | 2017-03-08 | 2021-01-06 | Agency for Science, Technology and Research | T-CELL RECEPTOR LIKE ANTIBODIES THAT BIND TO THE P53 MHC CLASS I COMPLEX |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| KR102945203B1 (ko) | 2017-05-08 | 2026-03-31 | 시애틀 프로젝트 코포레이션 | 알파바이러스 신생항원 벡터 |
| US11807662B2 (en) | 2017-05-16 | 2023-11-07 | The Johns Hopkins University | MANAbodies and methods of using |
| WO2019051127A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF |
| WO2019139896A1 (en) | 2018-01-09 | 2019-07-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
| AU2019321608B2 (en) | 2018-08-16 | 2024-07-25 | Biontech Us Inc. | T cell receptor constructs and uses thereof |
| CN111116732A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 针对egfr l858r基因突变的特异性tcr及其应用 |
| CN111116754A (zh) * | 2018-10-30 | 2020-05-08 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性tcr及其应用 |
| KR20210090650A (ko) | 2018-11-07 | 2021-07-20 | 그릿스톤 바이오, 인코포레이티드 | 알파바이러스 신생항원 벡터 및 인터페론 억제제 |
| GB2613715B (en) * | 2019-02-20 | 2023-12-06 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| CN111748026A (zh) * | 2019-03-29 | 2020-10-09 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| CN111777678A (zh) * | 2019-04-04 | 2020-10-16 | 天津亨佳生物科技发展有限公司 | 一种egfr l858r 新抗原表位肽及其在治疗肿瘤中的应用 |
| CN111848781A (zh) * | 2019-04-25 | 2020-10-30 | 天津亨佳生物科技发展有限公司 | 一种针对egfr l858r基因突变的特异性t细胞受体及其应用 |
| SG11202113187WA (en) | 2019-05-30 | 2021-12-30 | Gritstone Bio Inc | Modified adenoviruses |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| EP4030897A4 (en) * | 2019-09-20 | 2023-10-18 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| KR20220070487A (ko) * | 2019-09-26 | 2022-05-31 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 면역원성 egfr 펩타이드 조성물 및 암의 치료에서 그의 용도 |
| WO2021087840A1 (zh) * | 2019-11-07 | 2021-05-14 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
| CA3157411A1 (en) * | 2019-11-15 | 2021-05-20 | Karin Jooss | Antigen-binding proteins targeting shared neoantigens |
| AU2020402581A1 (en) | 2019-12-11 | 2022-06-23 | Molecular Partners Ag | Designed ankyrin repeat domains with altered surface residues |
| WO2021127184A1 (en) * | 2019-12-17 | 2021-06-24 | The Johns Hopkins University | MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| IL300026A (en) | 2020-08-06 | 2023-03-01 | Gritstone Bio Inc | Multiepitope vaccine cassettes |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| CN112300269B (zh) * | 2020-09-29 | 2022-12-09 | 中国科学院微生物研究所 | Kras突变特异性t细胞受体筛选及抗肿瘤用途 |
| WO2022082030A2 (en) | 2020-10-15 | 2022-04-21 | Gritstone Bio, Inc. | Antigen-binding proteins and related methods of use |
| WO2022099157A1 (en) * | 2020-11-06 | 2022-05-12 | Cue Biopharma, Inc. | Antigen presenting polypeptide complexes and methods of use thereof |
| WO2022155503A1 (en) | 2021-01-14 | 2022-07-21 | Gritstone Bio, Inc. | Multi-specific antibodies and methods of use |
| JP2024513651A (ja) | 2021-02-26 | 2024-03-27 | ニューヨーク ユニバーシティ | 共有結合性ペプチドコンジュゲートに結合する抗体を含む組成物及び方法 |
| CN114085281A (zh) * | 2021-10-15 | 2022-02-25 | 北京臻知医学科技有限责任公司 | 一种肿瘤抗原表位肽及其多聚体和应用 |
| WO2025217204A1 (en) * | 2024-04-08 | 2025-10-16 | The Johns Hopkins University | Methods and materials for treating p53+ cancers |
| WO2026062579A1 (en) | 2024-09-19 | 2026-03-26 | Comed Therapeutics Ltd. | Compositions and methods for protein delivery to cells |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630584B1 (en) * | 2000-03-16 | 2003-10-07 | Ramot At Tel-Aviv University Ltd. | Single chain antibody against mutant p53 |
| AU2003216341A1 (en) * | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| JP3738308B2 (ja) * | 2002-11-29 | 2006-01-25 | 篤 村口 | 抗原特異的リンパ球抗原受容体遺伝子のクローニング方法 |
| MXPA05014155A (es) * | 2003-06-27 | 2006-05-25 | Abgenix Inc | Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos. |
| US20060034850A1 (en) * | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| WO2006100681A2 (en) * | 2005-03-25 | 2006-09-28 | Ramot At Tel Aviv University Ltd. | Human synthetic single-chain antibodies directed against the common epitope of mutant p53 and their uses |
| CN101228187A (zh) * | 2005-03-25 | 2008-07-23 | 特拉维夫大学拉莫特有限公司 | 针对突变p53的共同表位的人合成单链抗体及其用途 |
| EA201401134A1 (ru) * | 2011-02-11 | 2015-05-29 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Hla-рестиктированные пептидоспецифические антигенсвязывающие белки |
-
2016
- 2016-03-23 EP EP16769561.8A patent/EP3286222A4/en active Pending
- 2016-03-23 WO PCT/US2016/023673 patent/WO2016154246A1/en not_active Ceased
- 2016-03-23 US US15/560,241 patent/US20180086832A1/en not_active Abandoned
- 2016-03-23 CA CA2980292A patent/CA2980292A1/en active Pending
- 2016-03-23 JP JP2017549815A patent/JP6944877B2/ja active Active
- 2016-03-23 CN CN202211294036.6A patent/CN115873129A/zh active Pending
- 2016-03-23 AU AU2016235251A patent/AU2016235251B2/en active Active
- 2016-03-23 CN CN201680028347.4A patent/CN108137685B/zh active Active
-
2021
- 2021-04-23 JP JP2021072976A patent/JP7304911B2/ja active Active
-
2022
- 2022-03-02 AU AU2022201421A patent/AU2022201421A1/en not_active Abandoned
-
2023
- 2023-04-11 JP JP2023063966A patent/JP2023085528A/ja active Pending
- 2023-07-12 US US18/351,087 patent/US20240166751A1/en active Pending
-
2025
- 2025-03-24 AU AU2025202102A patent/AU2025202102A1/en active Pending
-
2026
- 2026-03-10 JP JP2026037548A patent/JP2026090637A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016028251A (ja) | 発癌性融合タンパク質を検出するための近接媒介性アッセイ | |
| Zherdev et al. | Ways to reach lower detection limits of lateral flow immunoassays | |
| JP2016511417A5 (cg-RX-API-DMAC10.html) | ||
| JP2016001187A (ja) | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 | |
| CN108659120A (zh) | 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术 | |
| Bogen et al. | Molecular mechanisms of antigen retrieval: antigen retrieval reverses steric interference caused by formalin-induced cross-links | |
| EP2460874B1 (en) | Method of separating target cell in biological sample | |
| JP2013174616A (ja) | 抗体に基づくアレイを用いた乳癌療法のための薬物選択 | |
| Xin et al. | Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans | |
| US10401367B2 (en) | Method and apparatus for analyzing protein-protein interaction on single molecule level within the cellular environment | |
| CN105793709B (zh) | 用于使用半抗原和结合所述半抗原的抗体作为参照抗体的免疫测量的方法，以及用于使用所述参照抗体的免疫测量的装置 | |
| Drake et al. | Biophysical considerations for development of antibody-based therapeutics | |
| Ambrosetti et al. | Quantification of circulating cancer biomarkers via sensitive topographic measurements on single binder nanoarrays | |
| Sidhanth et al. | A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics | |
| Binder et al. | B‐cell receptor epitope recognition correlates with the clinical course of chronic lymphocytic leukemia | |
| Riera et al. | Precision and accuracy of receptor quantification on synthetic and biological surfaces using DNA-PAINT | |
| CN107923913A (zh) | 评估血细胞的细胞表面受体的方法 | |
| Goodrum et al. | Development of a silver nanoparticle embedded membrane platform for highly sensitive and multiplexed detection of extracellular vesicle proteins | |
| KR20130060009A (ko) | 표적 물질 검출 및 분리 장치, 및 이를 이용한 표적 물질 검출 및 분리 방법 | |
| CN110494543A (zh) | 通过声学的亲和细胞提取 | |
| JP2018519525A5 (cg-RX-API-DMAC10.html) | ||
| US20250147036A1 (en) | Methods for identification of antigen-binding molecules | |
| Kimble et al. | Novel antibodies for identification, selection, and manipulation of T cells expressing Whitlow linker-containing CARs | |
| Chiarella | Production, novel assay development and clinical applications of monoclonal antibodies | |
| JP2016533507A5 (cg-RX-API-DMAC10.html) |